Quick Answer
Stoke Therapeutics, Inc. reported Total Assets of $418.43 million for the year ending 2025.
- Stoke Therapeutics, Inc. showed an increase of +54.1% in Total Assets from 2024 to 2025.
- This data is from Stoke Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $246.37 million | Q3 2019: $238.83 million | Q1 2020: $220.84 million | Q2 2020: $210.21 million | Q3 2020: $199.94 million | Q1 2021: $278.91 million | Q2 2021: $264.45 million | Q3 2021: $253.77 million | Q1 2022: $315.94 million | Q2 2022: $301.43 million | Q3 2022: $277.63 million | Q1 2023: $281.80 million | Q2 2023: $256.92 million | Q3 2023: $239.89 million | Q1 2024: $205.18 million | Q2 2024: $307.76 million | Q3 2024: $293.32 million | Q1 2025: $406.89 million | Q2 2025: $384.51 million | Q3 2025: $360.26 million.
- Over the full 8 years of available data (2018 to 2025), Stoke Therapeutics, Inc.'s Total Assets has grown by 289.1%.
- Historical annual values: Fiscal year 2025: $418.43 million | Fiscal year 2024: $271.56 million | Fiscal year 2023: $228.34 million | Fiscal year 2022: $256.07 million | Fiscal year 2021: $238.87 million | Fiscal year 2020: $297.93 million | Fiscal year 2019: $228.75 million | Fiscal year 2018: $107.54 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: